Inhibitex Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Released: 11/02/10 07:00 AM
EDTInhibitex, Inc. (NASDAQ: INHX) announced today that three posters describing preclinical data on INX-189, the Company’s nucleotide polymerase inhibitor in clinical development for the treatment of chronic hepatitis C (HCV) infections, will be presented by various scientists from the Company at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA. The full abstracts can be viewed at the AASLD website at http://www.aasld.org/ .
The three posters will be presented during the HCV Therapy: Preclinical and Early Clinical Development Poster Session, today, November 2, 2010, from 7:00 am - 12:00 pm. The posters are as follows:
#1888; Kolykhalov et al., “Characterization of in vitro selected Hepatitis C Virus Replicon Mutants Resistant to the Phosphoramidate Analog of 2’-C-Methylguanosine, INX-189”
#1874; Hall et al., “Metabolite Characterization of INX-189, a Potent HCV Inhibitor, in Fresh Human Primary Hepatocytes and Human Liver and Kidney Cell Lines”
#1889; Vernachio, et al. “In Vitro and In Vivo Metabolism of INX-189, a Potent HCV Inhibitor, in Rat and Cynomolgus Monkey Hepatocytes”
About Inhibitex
The three posters will be presented during the HCV Therapy: Preclinical and Early Clinical Development Poster Session, today, November 2, 2010, from 7:00 am - 12:00 pm. The posters are as follows:
#1888; Kolykhalov et al., “Characterization of in vitro selected Hepatitis C Virus Replicon Mutants Resistant to the Phosphoramidate Analog of 2’-C-Methylguanosine, INX-189”
#1874; Hall et al., “Metabolite Characterization of INX-189, a Potent HCV Inhibitor, in Fresh Human Primary Hepatocytes and Human Liver and Kidney Cell Lines”
#1889; Vernachio, et al. “In Vitro and In Vivo Metabolism of INX-189, a Potent HCV Inhibitor, in Rat and Cynomolgus Monkey Hepatocytes”
About Inhibitex
,
ALSO SEE: 11/01/10
Inhibitex Initiates Phase 1b Multiple Ascending Dose Trial of INX-189 in Patients with Chronic Hepatitis C
Inhibitex Initiates Phase 1b Multiple Ascending Dose Trial of INX-189 in Patients with Chronic Hepatitis C
.
Video From September 21, 2010
Inhibitex, Inc., a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Company’s pipeline includes FV-100, which is in Phase II clinical development for the treatment of shingles, and INX-189, a nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C infections. The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development and has licensed the use of its proprietary MSCRAMM® protein platform to Pfizer for the development of staphylococcal vaccines. For additional information about the Company, please visit http://www.inhibitex.com/ .
Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex, Inc.
Contacts:
Inhibitex, Inc.
Russell H. Plumb, 678-746-1136
Chief Executive Officer
rplumb@inhibitex.com
or
The Trout Group
Lee M. Stern, CFA, 646-378-2922
lstern@troutgroup.com
Inhibitex, Inc., a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Company’s pipeline includes FV-100, which is in Phase II clinical development for the treatment of shingles, and INX-189, a nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C infections. The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development and has licensed the use of its proprietary MSCRAMM® protein platform to Pfizer for the development of staphylococcal vaccines. For additional information about the Company, please visit http://www.inhibitex.com/ .
Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex, Inc.
Contacts:
Inhibitex, Inc.
Russell H. Plumb, 678-746-1136
Chief Executive Officer
rplumb@inhibitex.com
or
The Trout Group
Lee M. Stern, CFA, 646-378-2922
lstern@troutgroup.com
No comments:
Post a Comment